



## **ALKERMES, INC.**

88 Sidney Street, Cambridge, MA 02139, US

---

### **Telephone**

+1 617 494 0171

---

### **Fax**

+1 617 494 9263

---

### **Web Site**

[www.alkermes.com](http://www.alkermes.com)

---

### **Contact Person**

Blair Jackson – Director, Business Development

---

### **Technology Specialisations**

Alkermes Injectable Extended Release and Pulmonary technologies enable delivery of complex macromolecules and small molecules to enhance drug formulations, creating valuable medical and commercial benefits.

#### **Injectable Drug Delivery Technologies**

ProLease and Medisorb are bioabsorbable, injectable, sustained-release systems for both small and macromolecules. Both may be used for either subcutaneous or intramuscular drug delivery.

Alkermes®' sustained-release systems are distinguished by:

- demonstrated safety, tolerability and sustained release of microspheres in all phases of human clinical trials;
- the potential to commercialise products that would otherwise not be viable;
- ability to manufacture products under a small laboratory scale, pilot scale or commercial manufacturing scale, with strict adherence to CGMPs.

#### **Pulmonary Drug Delivery Technology**

The AIR® Pulmonary Drug Delivery technology offers a unique, proprietary delivery system for optimised drug delivery to the lungs. Advantages over other delivery methods include:

- high-dose, efficient delivery;
- local or targeted delivery of wide dosage range;
- a small, convenient delivery device;
- demonstrated safety and efficacy in human clinical trials.

---

### **Corporate Relationships Sought**

- In-licensing opportunities for proprietary pipeline
  - Development and commercialisation partnerships using Alkermes' proprietary delivery systems
  - Out-licensing opportunities
-